Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

PURPOSE: TAS-102 is a novel oral agent combining the antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil (molar ratio 1:0.5). TAS-102 has shown good activity in refractory metastatic colorectal cancer with acceptable safety. No QT pr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Chemother Pharmacol
Päätekijät: Bendell, Johanna C., Patel, Manish R., Yoshida, Kenichiro, Seraj, Jabed, Weaver, Racquel, Lemech, Charlotte, Todaro, Thomas G., Pant, Shubham, Arkenau, Hendrik-Tobias
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2016
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882359/
https://ncbi.nlm.nih.gov/pubmed/27151157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3031-9
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia